2023
Effect of a Personalized Tobacco Treatment Intervention on Smoking Abstinence in Individuals Eligible for Lung Cancer Screening
Cartmel B, Fucito L, Bold K, Neveu S, Li F, Rojewski A, Gueorguieva R, O'Malley S, Herbst R, Toll B. Effect of a Personalized Tobacco Treatment Intervention on Smoking Abstinence in Individuals Eligible for Lung Cancer Screening. Journal Of Thoracic Oncology 2023, 19: 643-649. PMID: 37977486, PMCID: PMC10999350, DOI: 10.1016/j.jtho.2023.11.012.Peer-Reviewed Original ResearchStandard of careLung cancer screeningCancer screeningQuit ratesGain-framed messagingPack-year smoking historySmoking cessation ratesSmoking quit ratesNumber of cigarettesTobacco treatment interventionsYears of ageCessation/reductionChi-square testSelf-reported numberSmoking historyStandard careCessation ratesRandomized trialsTobacco treatmentTobacco cessationBiomarker feedbackLung cancerSmoking abstinencePost randomizationSmoking behavior
2021
Practical Considerations Relating to Routine Clinical Biomarker Testing for Non–small Cell Lung Cancer: Focus on Testing for RET Fusions
Herbst RS, Aisner DL, Sonett JR, Turk AT, Weintraub JL, Lindeman NI. Practical Considerations Relating to Routine Clinical Biomarker Testing for Non–small Cell Lung Cancer: Focus on Testing for RET Fusions. Frontiers In Medicine 2021, 7: 562480. PMID: 33553195, PMCID: PMC7859651, DOI: 10.3389/fmed.2020.562480.Peer-Reviewed Original ResearchNon-small cell lung cancerCell lung cancerLung cancerAdvanced non-small cell lung cancerGenomic profilingExpert consensus guidanceMultidisciplinary advisory boardAccurate histopathological diagnosisGenomic screening programDrug Administration approvalProto-oncogene tyrosine-protein kinase receptor RetNumber of biomarkersStandard careInvestigational agentsTargetable alterationsHistopathological diagnosisRET fusionsActionable biomarkersAdministration approvalBiomarker testingScreening programSurgical pathologistsSpecific small molecule inhibitorsTreatment selectionBiopsy tissue